Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 12/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.49 |
| ▸ | TEC | P42680 | 1/20 | 0.49 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465790 | 1.00 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL29465791 | 1.00 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL2453138 | 1.00 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL28983490 | 0.95 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL29834734 | 0.94 | PIK3CD (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL29834791 | 0.94 | PIK3CD (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL24714039 | 0.90 | ENPP1 (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL30822064 | 0.90 | ENPP1 (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL22598590 | 0.90 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGEGFR | |
| SCHEMBL29465805 | 0.90 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | HENNEQUIN LAURENT FRANCOIS ANDRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | HENNEQUIN LAURENT FRANCOIS ANDRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | HENNEQUIN LAURENT FRANCOIS ANDRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| EP-1667991-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1667991-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1658280-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005026150-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005014582-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | VEGFA, KDR, FLT1 | PIK3CD 1389/4885PIK3CA 805/4885PIK3CB 1988/4885 |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | PIK3CD 300/4885PIK3CA 202/4885PIK3CB 301/4885 |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, KDR, FLT1 | PIK3CD 1554/4885PIK3CA 1005/4885PIK3CB 2164/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | PIK3CD 284/4885PIK3CA 186/4885PIK3CB 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.